ADAM-12 (Recombinant)

Recombinant Protein · expressed in HEK293
Citation tracking pending
Human ADAM-12 (O43184) expressed in HEK293 cells. Suited for metalloproteinase activity assays, inhibitor IC50 screens, substrate cleavage studies, and antibody validation as a positive control standard.
Expression system
HEK293
Cat. #
REC-ADAM12

In stock

SKU
REC-ADAM12
$498.00

Target Overview

ADAM-12 (Disintegrin and metalloproteinase domain-containing protein 12; UniProt O43184) is a 909-amino-acid type I transmembrane metalloproteinase of the ADAM family, encoded by the ADAM12 gene. The full-length protein carries the canonical ADAM domain architecture: a prodomain, a zinc-dependent metalloproteinase catalytic domain (EC 3.4.24.-), a disintegrin domain, a cysteine-rich domain, an EGF-like domain, a transmembrane segment, and a cytoplasmic tail. It localises to the cell membrane, where it participates in ectodomain shedding and cell-cell fusion events. This recombinant is produced in HEK293 mammalian cells, providing human-derived post-translational modifications — including glycosylation patterns relevant to the native protein — that are not accessible from prokaryotic expression systems. Mammalian expression is particularly important for ADAM family members whose folding and disulfide bonding are sensitive to the expression host. Researchers use this reagent in several in vitro contexts. In enzymatic activity assays, it serves as the enzyme source against fluorogenic or natural peptide substrates to characterise cleavage specificity. In inhibitor screening workflows, it enables IC50 determination for hydroxamate-based or other metalloproteinase inhibitor series. Because ADAM-12 has been studied in connection with TGF-β signalling, HB-EGF shedding, and extracellular matrix remodelling, it is also used in substrate-identification experiments by mass spectrometry. As a well-defined, sequence-verified protein standard, it functions as a positive control antigen in Western blot and IHC antibody validation workflows. Researchers validating Triple Point Biologics' matched anti-ADAM-12 antibody (SKU: RP-ADAM12) routinely use this recombinant as the paired positive control.

Background

ADAM-12 (Meltrin-alpha) belongs to the ADAM (A Disintegrin And Metalloproteinase) family of zinc-dependent sheddases. Its characterised biological roles include skeletal muscle cell fusion during regeneration and the formation of macrophage-derived giant cells and osteoclasts from mononuclear precursors. At the molecular level, ADAM-12 mediates ectodomain shedding of membrane-anchored growth factors and receptors — notably heparin-binding EGF-like growth factor (HB-EGF) — positioning it as a regulator of multiple receptor tyrosine kinase and cytokine signalling axes. Published research has implicated ADAM-12 in a range of tissue and disease contexts that are actively studied with in vitro recombinant protein tools. In rheumatoid arthritis models, Lin et al. (2026) demonstrated ADAM-12 involvement in TGF-β1-induced proliferation of synovial fibroblasts, providing a mechanistic rationale for its study in fibrotic and inflammatory signalling assays. In oncology research, Wu et al. (2026) reported that ADAM-12 stabilises the translation initiation factor EIF3B to promote glycolysis and tumour progression in hepatocellular carcinoma cell lines, characterising a non-proteolytic scaffolding function that expands the mechanistic scope beyond simple sheddase activity. In salivary gland malignancies, Tavares et al. (2026) used immunohistochemical analysis to profile ADAM-12 alongside HIF-1α, NOTCH-1, and HB-EGF in adenoid cystic and mucoepidermoid carcinomas, illustrating how ADAM-12 protein-level studies in tumour stroma inform understanding of hypoxic adaptation. Additionally, ADAM-12 has been identified among hypoxia-related gene signatures with prognostic associations in lung adenocarcinoma (Alghamdi, 2026), further establishing it as a transcriptionally regulated target of interest in tumour microenvironment research. Beyond cancer and inflammation, ADAM-12 has been studied in the context of cytoskeletal remodelling, mechanosensing, and podosome-associated extracellular matrix dynamics (Velmurugan et al., 2026), extending its relevance to cell migration and invasion assays. This breadth of published applications — spanning enzyme kinetics, growth factor shedding, fibroblast signalling, glycolysis regulation, and ECM biology — makes a sequence-verified, mammalian-expressed ADAM-12 recombinant a useful reagent across multiple research programmes. Researchers requiring an orthogonal detection tool for ADAM-12 in parallel experiments can pair this recombinant with the Triple Point Biologics anti-ADAM-12 antibody (SKU: RP-ADAM12), validated for Western blot.

Applications

  • Metalloproteinase activity assay using fluorogenic peptide substrates to measure ADAM-12 catalytic rate and specificity
  • Inhibitor IC50 determination for hydroxamate-class or small-molecule metalloproteinase inhibitors against ADAM-12
  • Substrate identification by mass spectrometry — recombinant ADAM-12 incubated with candidate ectodomain substrates (e.g., HB-EGF, fibronectin fragments)
  • Positive control antigen for Western blot validation of anti-ADAM-12 antibodies, including the matched Triple Point Biologics RP-ADAM12 antibody
  • Positive control antigen for IHC protocol optimisation and antibody titre determination
  • TGF-β1 signalling reconstitution assays examining ADAM-12-dependent fibroblast proliferation or shedding events in cell-free systems
  • EIF3B–ADAM-12 protein–protein interaction studies (co-immunoprecipitation, pull-down, or surface plasmon resonance) based on published scaffolding function
  • ELISA standard curve preparation for quantification of ADAM-12 in conditioned media or tissue lysates

References

  1. Alghamdi B. Exploring hypoxia-related genes as prognostic indicators in lung adenocarcinoma. PLoS One. 2026. doi:10.1371/journal.pone.0349820. PMID: 42234659
  2. Tavares TSDC et al. Parenchymal and stromal adaptations to hypoxia in adenoid cystic carcinoma and mucoepidermoid carcinoma: a comparative immunohistochemical analysis of HIF-1α, NOTCH-1, ADAM-12 and HB-EGF. Oral Surg Oral Med Oral Pathol Oral Radiol. 2026. doi:10.1016/j.oooo.2026.04.003. PMID: 42128786
  3. Wu S et al. ADAM12 Stabilizes EIF3B to Promote Glycolysis and Tumor Progression in Hepatocellular Carcinoma. J Hepatocell Carcinoma. 2026. doi:10.2147/JHC.S560478. PMID: 42117088
  4. Lin D et al. Involvement of ADAM12 in TGF-β1-Induced Proliferation of Rheumatoid Arthritis Synovial Fibroblasts. Acta Med Okayama. 2026. doi:10.18926/AMO/70450. PMID: 42025429
  5. Velmurugan G et al. The dynamics of podosomes, extracellular matrix-associated proteins regulate the cytoskeletal remodeling, mechanosensing, migration in Tau. Adv Protein Chem Struct Biol. 2026. doi:10.1016/bs.apcsb.2025.10.021. PMID: 41904004

Additional Specifications

Storage Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM CaCl₂, 10% glycerol
Endotoxin Level <0.1 EU/µg by LAL
Purity (%) >90% by SDS-PAGE
Expression System HEK293
Subcellular Localization Type I transmembrane; cell surface; Golgi → endosomes

Frequently Asked Questions

What molecular weight does recombinant ADAM-12 run at on SDS-PAGE and Western blot?

The full-length ADAM-12 protein (UniProt O43184) has a predicted MW of ~100 kDa from its 909-amino-acid sequence, but our HEK293-expressed recombinant typically migrates at ~120–130 kDa under reducing SDS-PAGE conditions. The upward shift reflects N-linked glycosylation added during mammalian expression — a pattern not replicated in E. coli systems. Under non-reducing conditions, disulfide-stabilized forms may migrate anomalously. If you are running this alongside RP-ADAM12 antibody blots, expect the glycosylated band at ~120–130 kDa.

Which isoform and processing form of ADAM-12 is this recombinant — full-length, prodomain removed, soluble ectodomain?

This recombinant corresponds to the soluble ectodomain of ADAM-12 (the predominant shed form), spanning the metalloproteinase, disintegrin, cysteine-rich, and EGF-like domains, with the prodomain removed to yield the active enzyme. The transmembrane segment and cytoplasmic tail are absent. This matches the ADAM-12 form most commonly detected in conditioned media and serum-based functional studies. Researchers studying full-length membrane-anchored ADAM-12 topology should note this distinction when designing cell-surface localization or co-immunoprecipitation experiments.

What substrates can I use to measure ADAM-12 metalloproteinase activity in a fluorescence assay?

ADAM-12 cleaves fluorogenic peptide substrates based on the consensus ADAM cleavage motif. A well-validated choice is the quenched fluorescent peptide Mca-KPLGL-Dpa-AR-NH2 (excitation ~320 nm, emission ~405 nm), used widely for ADAM family activity assays. IGFBP-3 and IGFBP-5 are documented protein substrates if you prefer a gel-based or ELISA readout. Run reactions in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM CaCl2, at 37°C. Confirm zinc dependence with 10 mM EDTA as a negative control.

What is a good starting concentration of recombinant ADAM-12 for an in vitro activity assay, and how should I optimize it?

A practical starting point is 50–200 nM recombinant ADAM-12 with 5–20 µM fluorogenic substrate in a 100 µL reaction volume, incubated at 37°C for 30–60 minutes. Titrate enzyme from 25 to 400 nM while holding substrate constant to establish the linear range. Avoid BSA carriers in the assay buffer, as they can quench fluorescence signals. If using inhibitor IC50 studies, fix enzyme at the lowest concentration giving a robust signal (typically ~50 nM) to avoid substrate depletion artifacts during the assay window.

Does the storage buffer for recombinant ADAM-12 interfere with common metalloproteinase activity assays?

The supplied storage buffer — 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol, 5 mM CaCl2 — is generally compatible with fluorogenic peptide assays at typical dilutions (1:10 or greater into assay buffer). The 10% glycerol is carried over only in trace amounts at working dilutions and does not inhibit ADAM-12 activity at these levels. The 5 mM CaCl2 supports metalloproteinase stability. Do not dilute into EDTA- or EGTA-containing buffers; chelation of Ca²⁺ and Zn²⁺ will inactivate the enzyme irreversibly.

Can I use recombinant ADAM-12 as a positive control for Western blot with the RP-ADAM12 rabbit polyclonal antibody?

Yes — this is a primary validated use case. REC-ADAM12 and RP-ADAM12 are produced and cross-validated in the same lab, so the antibody is confirmed to recognize the recombinant protein on Western blot. Load 50–100 ng of REC-ADAM12 per lane alongside your cell lysates; the glycosylated ectodomain band at ~120–130 kDa serves as a clean size marker. This pairing is also useful for antibody lot-to-lot consistency checks. See the RP-ADAM12 product page (/anti-adam-12-rabbit-polyclonal-antibody) for recommended antibody dilutions and blocking conditions.

How much recombinant ADAM-12 should I load as a Western blot positive control, and will it cause signal saturation?

For standard chemiluminescent detection with RP-ADAM12, 50 ng per lane gives a strong, non-saturated band under typical ECL exposure conditions. If you are titrating antibody concentration or comparing signal across low-abundance lysate samples, a 25–50 ng range keeps the positive control within the linear detection window and avoids blooming that could obscure adjacent lanes. For fluorescent Western systems (e.g., LI-COR), 25 ng is usually sufficient. Run a small titration (10, 25, 50, 100 ng) on your first experiment to calibrate your specific detection setup.

How should I handle, aliquot, and store recombinant ADAM-12 to maintain activity over time?

The protein is supplied in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol, 5 mM CaCl2. Store at −20°C in single-use aliquots immediately upon receipt; the glycerol concentration supports stability at this temperature without requiring −80°C. Repeated freeze-thaw cycles progressively reduce metalloproteinase activity — plan aliquot sizes around your typical single-experiment usage. Once thawed, keep on ice and use within the same working session. Do not store thawed aliquots at 4°C for more than 24 hours; activity loss is measurable within that window for ADAM family enzymes.

Validation imagery coming soon

Western blot validation figures for REC-ADAM12 will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →